Full Title
A Phase I Trial of CD19-targeted Chimeric Antigen Receptor (CAR) T Cells That Constitutively Secrete Interleukin 18 (19-28z/IL-18) in Patients with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)Purpose
Researchers are assessing a CAR T cell therapy to treat acute lymphoblastic leukemia (ALL) that keeps growing even with treatment. With CAR T cell therapy, some of your own T cells (a type of white blood cell) are removed. They are genetically modified (changed) in a lab to recognize your own cancer cells. The altered T cells, called CAR T cells, are then returned to your body to find and kill cancer cells. This treatment is a form of immunotherapy.
The CAR T cell therapy in this study is called 19-28z/IL-18. The modified T cells recognize a protein on cancer cells called CD19. They release another protein called IL-18 that may increase the effectiveness of the CAR T cells.
Before you get 19-28z/IL-18, you may receive fludarabine and cyclophosphamide. These chemotherapy drugs briefly weaken your immune system and help prepare your body to receive the CAR T cells. The treatments in this study are given intravenously (by vein).
Contact
For more information and to see if you or your child can join this study, please call Dr. Jae Park’s office at 888-675-2278 (CART).